Showing results (121-130 of 257) with videos related to

Sort By:
Pageof 26
Haematologica|January 19, 2007
Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working PartyGianantonio Rosti, Ilaria Iacobucci, Simona Bassi, et al.
Mediterranean Journal of Hematology and Infectious Diseases|June 18, 2019
Treatment Patterns in Patients with Chronic-Phase Chronic Myeloid Leukaemia in Routine Clinical Practice: the SIMPLICITY Italian PopulationElisabetta Abruzzese, Alberto Bosi, Massimo Breccia, et al.
The New England Journal of Medicine|January 29, 2015
Ruxolitinib versus standard therapy for the treatment of polycythemia veraAlessandro M Vannucchi, Jean Jacques Kiladjian, Martin Griesshammer, et al.
European Journal of Haematology|November 27, 2015
Changes in quality of life and disease-related symptoms in patients with polycythemia vera receiving ruxolitinib or standard therapyRuben Mesa, Srdan Verstovsek, Jean-Jacques Kiladjian, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 25, 2024
Deep Molecular Response Rate in Chronic Phase Chronic Myeloid Leukemia: Eligibility to Discontinuation Related to Time to Response and Different Frontline TKI in the Experience of the Gimema Labnet CML National NetworkMassimo Breccia, Rosalba Cucci, Giovanni Marsili, et al.
Clinical Chemistry|March 9, 2013
Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scaleHelen E White, John Hedges, Israel Bendit, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2009
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular responseFrancesca Palandri, Ilaria Iacobucci, Simona Soverini, et al.
Hematological Oncology|July 7, 2023
Ultrasonography-guided core-needle biopsy of lymphadenopathies suspected of lymphoma: Analysis on diagnostic efficacy and safety of 1000 front-line biopsies in a multicenter Italian studyMarco Picardi, Claudia Giordano, Elena Vigliar, et al.
Haematologica|December 31, 2011
Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinibDeborah L White, Jerald Radich, Simona Soverini, et al.
Blood|February 13, 2009
Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working PartyFausto Castagnetti, Francesca Palandri, Marilina Amabile, et al.
Pageof 26